Esperion Says It Enters Into A Royalty Purchase Deal With Omers Life Sciences, Under Which It Got $304.7M In Exchange For 100% Interest In Esperion's Royalty Entitlement On Daiichi Sankyo Europe's Net Sales Of Bempedoic Acid Products In Europe
Portfolio Pulse from Benzinga Newsdesk
Esperion has entered into a royalty purchase deal with Omers Life Sciences, receiving $304.7 million in exchange for 100% interest in its royalty entitlement on Daiichi Sankyo Europe's net sales of Bempedoic Acid products in Europe.
June 28, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion has entered into a royalty purchase deal with Omers Life Sciences, receiving $304.7 million in exchange for 100% interest in its royalty entitlement on Daiichi Sankyo Europe's net sales of Bempedoic Acid products in Europe.
The deal provides Esperion with a significant cash infusion of $304.7 million, which can be used to fund operations, R&D, or other strategic initiatives. This is likely to be viewed positively by investors as it strengthens the company's financial position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100